Search
for
Sort by
Research 30 of 1000+
- Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
- New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- Redefining hormone resistance in prostate cancer
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
- Characteristics of flutamide action on prostatic and testicular functions in the rat
- Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer
- Low-Dose Dimethyl Sulfoxide (DMSO) Suppresses Androgen Receptor (AR) and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer (CRPC) Cells
- Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Prostate Carcinoma, what would be the best to do ?
- COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
- Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry
- Two cases of low-prostate-specific antigen localized prostate cancer incidentally detected by computed tomography
- Diseases of the Canine Prostate Gland
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
- Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
- 5α- Reductase Inhibitors in Prostate Cancer: An Overview
- The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
- Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
- Anti-proliferative effect of terpenes on human prostate cáncer cells: natural sources and their potential role as chemopreventive agents.
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways
- Steroidogenesis in steroid related cancers
- Drug safety evaluation of exemestane
- Is dehydroepiandrosterone a hormone?
- Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
- Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study